Stocks Health care FBRX
NASDAQ · Health careForte Biosciences, Inc. (FBRX)
It posted a net loss of $87.9M. In fiscal 2025 capital spending exceeded operating cash flow by $51M. At June 30, 2026 it held $49.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
Key facts about Forte Biosciences, Inc.
- Net worth
- Forte Biosciences, Inc. has a market value (market cap) of $1.6B at the latest share price, and shareholders' equity of $183.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2019 revenue was $36K (-99.8% year on year), with a net loss of $4.1M.
- Cash flow
- In fiscal 2025 operations used $50.9M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 12, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
What Forte Biosciences, Inc. does
Forte Biosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker FBRX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$69.4M | -$4.71 | -$51M |
| 2024 | n/a | -$35.5M | -$12.17 | -$30.8M |
| 2023 | n/a | -$31.5M | -$24.92 | -$28.8M |
| 2022 | n/a | -$13.9M | -$19.94 | n/a |
| 2021 | n/a | -$21.7M | -$38.63 | n/a |
| 2020 | n/a | -$46.5M | -$157.49 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Forte Biosciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 4, 2026Passive stake changed SCHEDULE 13G/A
- September 8, 2026Deregistration 15-12G
- September 8, 2026Deregistration 15-12G
- September 8, 2026Deregistration 15-12G
- August 27, 2026Form POS AM filing POS AM
- August 27, 2026Form POS AM filing POS AM
- August 27, 2026Form POS AM filing POS AM
- August 27, 2026Form POS AM filing POS AM
- August 27, 2026Form POS AM filing POS AM
- August 27, 2026Form POS AM filing POS AM
Insider trades
What the people running Forte Biosciences, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 4 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 27, 2026 | Gryska David WDirector | Other change | 5,940 | - |
| August 27, 2026 | Riley Antony ACHIEF FINANCIAL OFFICER | Other change | 42,600 | - |
| August 27, 2026 | Wagner Paul A.SEE REMARKS, Director | Other change | 85,482 | - |
| August 27, 2026 | Kornfeld StevenDirector | Other change | 3,960 | - |
| July 1, 2026 | Riley Antony ACHIEF FINANCIAL OFFICER | Exercised options | 375 | - |
| July 1, 2026 | Riley Antony ACHIEF FINANCIAL OFFICER | Shares withheld for tax | 134 | $2.9K |
| July 1, 2026 | Wagner Paul A.SEE REMARKS, Director | Exercised options | 1,250 | - |
| July 1, 2026 | Wagner Paul A.SEE REMARKS, Director | Shares withheld for tax | 98 | $2.1K |
Who owns FBRX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| JANUS HENDERSON GROUP Ltd.13G, passive | 9.3% | August 13, 2026 |
| MPM BioImpact LLC13G, passive | 7.2% | May 15, 2026 |
| Orbimed Advisors LLC13G, passive with 2 related filers | 6.2% | August 14, 2026 |
| Affinity Asset Advisors, LLC13G, passive with 1 related filers | 5.6% | August 13, 2026 |
Largest institutional holders
Insiders
Questions about FBRX
What does Forte Biosciences, Inc. do?
Forte Biosciences, Inc. is a company in the Health care sector, listed on NASDAQ as FBRX. Its shares trade on NASDAQ under the ticker FBRX.
What is Forte Biosciences, Inc.'s net worth?
Forte Biosciences, Inc. has a market value (market cap) of $1.6B at the latest share price, and shareholders' equity of $183.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Forte Biosciences, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $87.9M.
When did Forte Biosciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake changed from November 4, 2026.
Similar companies
Compare FBRX with
Follow FBRX
Get an email when Forte Biosciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Forte Biosciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.